SEC Tracker
Get the app

Gilead Sciences GILD

Gilead Sciences Q1 FY26: revenue $7.0B, up 4%; diluted EPS $1.61

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Gilead Sciences reported for Q1 FY26, the quarter ended Mar 31, 2026, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$7.0B+4% from $6.7B in Q1 FY2510-Q income statement, on EDGAR
  2. Net income$2.0B+54% from $1.3B in Q1 FY2510-Q income statement, on EDGAR
  3. Diluted EPS$1.61+55% from $1.04 in Q1 FY2510-Q income statement, on EDGAR
  4. Cash and cash equivalents$7.6B−4% from $7.9B in Q1 FY25Cash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
  5. Cash from operations$2.5B+45% from $1.8B in Q1 FY2510-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Gilead Sciences files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Bristol Myers Squibb BMY public float $94.2B, Jun 30, 2025
  2. Vertex Pharmaceuticals VRTX public float $113.4B, Jun 30, 2025
  3. Pfizer PFE public float $138.0B, Jun 29, 2025
  4. Amgen AMGN public float $150.1B, Jun 30, 2025
  5. Zoetis ZTS public float $69.2B, Jun 30, 2025